Dodging COVID-19 infection: low expression and localization of ACE2 and TMPRSS2 in multiple donor-derived lines of human umbilical cord-derived mesenchymal stem cells

[1] Hoffmann M(2020)SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Cell. 181 271-280.e8

[2] Kleine-Weber H(2013)Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor Nature 503 535-538

[3] Schroeder S(2005)A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury Nat Med 11 875-879

[4] Krüger N(2020)Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China Clin Infect Dis. 71 762-768

[5] Herrler T(2016)The cytokine storm of severe influenza and development of immunomodulatory therapy Cell Mol Immunol. 13 3-10

[6] Erichsen S(2020)Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Lancet 395 497-506

[7] Schiergens TS(2020)Mesenchymal stem cells and management of COVID-19 pneumonia Med Drug Discov 5 100019-755

[8] Herrler G(2020)Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know Ann Intern Med. 172 754-345

[9] Wu NH(2020)A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 J Crit Care. 57 279-650

[10] Nitsche A(2010)Adult mesenchymal stem cells: an innovative therapeutic for lung diseases Discov Med. 9 337-318

[1] Hoffmann M(2020)SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Cell. 181 271-280.e8

[2] Kleine-Weber H(2013)Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor Nature 503 535-538

[3] Schroeder S(2005)A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury Nat Med 11 875-879

[4] Krüger N(2020)Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China Clin Infect Dis. 71 762-768

[5] Herrler T(2016)The cytokine storm of severe influenza and development of immunomodulatory therapy Cell Mol Immunol. 13 3-10

[6] Erichsen S(2020)Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Lancet 395 497-506

[7] Schiergens TS(2020)Mesenchymal stem cells and management of COVID-19 pneumonia Med Drug Discov 5 100019-755

[8] Herrler G(2020)Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know Ann Intern Med. 172 754-345

[9] Wu NH(2020)A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 J Crit Care. 57 279-650

[10] Nitsche A(2010)Adult mesenchymal stem cells: an innovative therapeutic for lung diseases Discov Med. 9 337-318